Aspen Pharma Brasil

aspenpharma.com.br

Aspen Pharma Brazil is a subsidiary of Aspen Pharmacare, the leading brand in Africa and one of the 20 largest branded generic brand in the world. Aspen Pharmacare has 18 production plants in 14 countries on six continents, and supplies medicines to more than 150 countries. The Group officially entered the Brazilian drug market in 2009 after acquiring 100% of Cellofarm, headquartered in Rio de Janeiro. Aspen do Brasil's mission is to supply the domestic market, in addition to ensuring the Group's expansion in Latin America, focusing on growth through global acquisitions with other multinationals.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More

Pharmacy Market

NRX PHARMACEUTICALS TO WORK WITH CARDINAL HEALTH TO ENSURE EFFICIENT DISTRIBUTION OF POTENTIAL THERAPIES

NRx Pharmaceuticals | August 26, 2021

news image

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure. "This partnership creates an efficient and highly flexible lo...

Read More

Pharma Tech

DOUGLAS PHARMACEUTICALS FORMS LEAD PROGRAM R-107 CLINICAL ADVISORY BOARD

Douglas Pharmaceuticals | January 27, 2023

news image

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are ver...

Read More

Pharmacy Market

EYENOVIA'S NOVEL OPTEJET® DISPENSER PUTS PEOPLE'S EYES FIRST

Eyenovia | September 06, 2022

news image

Eyenovia, Inc. an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser. Traditional eye drops normally overdose the patient's eye with medication and preservatives. Eyenovia's easy-to-use, novel Optejet® dispenser administers precisely 8µL of medication to the eye, effectively treating the patient's condition while creating a...

Read More
news image

Business Insights

HIKMA STRENGTHENS US INJECTABLES BUSINESS THROUGH ACQUISITION OF CUSTOPHARM

Hikma Pharmaceuticals USA Inc. | September 27, 2021

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, today announces that it has agreed to acquire Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'). Hikma will pay an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certa...

Read More
news image

Pharmacy Market

NRX PHARMACEUTICALS TO WORK WITH CARDINAL HEALTH TO ENSURE EFFICIENT DISTRIBUTION OF POTENTIAL THERAPIES

NRx Pharmaceuticals | August 26, 2021

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure. "This partnership creates an efficient and highly flexible lo...

Read More
news image

Pharma Tech

DOUGLAS PHARMACEUTICALS FORMS LEAD PROGRAM R-107 CLINICAL ADVISORY BOARD

Douglas Pharmaceuticals | January 27, 2023

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are ver...

Read More
news image

Pharmacy Market

EYENOVIA'S NOVEL OPTEJET® DISPENSER PUTS PEOPLE'S EYES FIRST

Eyenovia | September 06, 2022

Eyenovia, Inc. an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics, brings human-centric design to ophthalmology with its novel Optejet® dispenser. Traditional eye drops normally overdose the patient's eye with medication and preservatives. Eyenovia's easy-to-use, novel Optejet® dispenser administers precisely 8µL of medication to the eye, effectively treating the patient's condition while creating a...

Read More